Abstract:
A method for treating a glycoprotein-related disease is disclosed, which comprises: administering a first effective amount of phenol red and a second effective amount of an organic arsenic compound to a subject in need thereof.

Description:
CROSS REFERENCE TO RELATED APPLICATION 
       [0001]    This application claims the benefits of the Taiwan Patent Application Serial Number 104127036, filed on Aug. 19, 2015, the subject matter of which is incorporated herein by reference. 
         [0002]    This application also claims the benefits of the Taiwan Patent Application Serial Number 105106052, filed on Feb. 27, 2016, the subject matter of which is incorporated herein by reference. 
       BACKGROUND 
       [0003]    1. Field of the Invention 
         [0004]    The present invention relates to a pharmaceutical composition and a method for treating a glycoprotein-related disease and, more particularly, to a pharmaceutical composition and a method for treating a glycoprotein-related disease with phenol red and an organic arsenic compound. 
         [0005]    2. Description of Related Art 
         [0006]    Currently, clinical treatment of viral diseases is mainly based on supportive therapy. Supportive therapy involves fluid therapy and nutrition supplementation to help patients recuperate and to increase immunity. It also involves concurrent administration of broad-spectrum antibiotics to prevent secondary infection. However, whether viral diseases can be cured depends on individual&#39;s immunity. 
         [0007]    Treatment of snake venom infection requires an initial determination of the infection to be hemorrhagic venom infection or neurotoxic venom infection. Administration of anti-snake venom serum then follows to neutralize toxicity and to increase immunity. With concurrent administration of antibiotics, healing time of wounds with redness and swelling is over 7 days. 
         [0008]    Prion infection, such as bovine spongiform encephalopathy, scrapie, and Creutzfeldt-Jakob disease, is caused by abnormal cellular metabolism due to glycosylation between carbohydrates and proteins in brain cells. Such abnormal cellular metabolism results in denaturation of proteins to infective proteins as well as deposition and aggregation of glycoproteins and amyloids to induce neuropathy. Until now, there is still no effective drug treatment and prevention for Prion infection. 
         [0009]    Toxic protein infection by insects and reptiles, such as mosquitoes, bees, scorpions, spiders, centipedes, ants, and staphylinidae, is caused by injection of toxic proteins into mankind and animals by stinging. The result ranges from redness, swelling, allergy, itching, and inflammation of skin to fever. Such insects and reptiles also play roles as media or carriers of viruses, such as dengue viruses that belong to Flaviviridae and Flavivirus, West Nile virus, and Zika virus, to infect mankind and animals. 
         [0010]    Cell abnormality includes pathological changes of eye cells, brain cells, and cellular metabolism. Cataract, one of the pathological changes of eye cells, is caused by abnormal metabolism and degeneration in the elderly. Such abnormal metabolism and degeneration result in abnormal glycosylation between carbohydrates and proteins in cells of eye lens. Cataract membrane formation due to deposition and aggregation of protein fibers leads to blurred vision. The current treatment of cataract includes surgical removal and laser treatment. However, such treatments are not completely pain-free and have risks for blindness as well as high surgery cost. Retinopathy, another pathological change of eye cells, is caused by glycosylation between carbohydrates and proteins in photoreceptors cells of fiber membrane and choroidal membrane of retina. Such glycosylation leads to degeneration and vision loss. The treatment of retinopathy generally includes supplementation of vitamin A and lutein. However, such treatment has no active therapeutic effect. 
         [0011]    Alzheimer&#39;s disease, one of the pathological changes of brain cells, is also caused by glycosylation between carbohydrates and proteins in brain cells. Such glycosylation results in abnormal cellular metabolism as well as deposition and aggregation of glycoproteins and amyloids. These induce symptoms of dementia, memory loss, and degeneration of the elderly. Currently, there is no effective prevention and treatment of Alzheimer&#39;s disease. Parkinson&#39;s disease is also caused by glycosylation between carbohydrates and proteins in neurons of brain. Such glycosylation results in abnormal metabolism, neurodegeneration, as well as deposition and aggregation of amyloids and fibrins, leading to chronic neurological symptoms. There is also no prevention and effective treatment of Parkinson&#39;s disease. 
         [0012]    Pancreatitis, a pathological change of cellular metabolism, is caused by glycosylation between carbohydrates and proteins in pancreatic cells. Such glycosylation results in abnormal cellular metabolism, degeneration, as well as deposition and aggregation of glycoproteins and amyloids. These lead to swelling of pancreas, acute and chronic inflammation, and fibrosis of pancreas. Such pancreatitis is often categorized as having unknown causes medically. Treatment of such pancreatitis depends on autologous immunity. There is no effective drug treatment for such pancreatitis. Kidney inflammation is caused by glycosylation between carbohydrates and proteins in renal cells. Such glycosylation results in abnormal cellular metabolism and degeneration as well as deposition and aggregation of amyloids. These lead to swelling of kidney, acute and chronic inflammation, and fibrosis of kidney. Such kidney inflammation is often categorized as having unknown causes medically. There is no effective drug treatment for such kidney inflammation. Hepatitis and cholangitis are caused by glycosylation between carbohydrates and proteins in hepatic cells. Such glycosylation results in abnormal cellular metabolism as well as deposition and aggregation of glycoproteins and amyloids. These lead to swelling and inflammation of liver and bile duct as well as fibrosis of liver. Medically, such hepatitis and cholangitis are categorized as acute fulminating hepatitis, acute hepatitis, acute cholangitis, or having other unknown causes. There is no effective drug treatment for such hepatitis and cholangitis. 
         [0013]    Accordingly, there is a need to develop an effective drug for treating the aforesaid diseases. 
       SUMMARY 
       [0014]    The present disclosure provides a method for treating a glycoprotein-related disease, which comprises: administering a first effective amount of phenol red and a second effective amount of an organic arsenic compound to a subject in need thereof. 
         [0015]    The present disclosure also provides a pharmaceutical composition for treating a glycoprotein-related disease in a subject in need thereof, which comprises: a first effective amount of phenol red and a second effective amount of an organic arsenic compound. 
         [0016]    Furthermore, the present disclosure provides a use of a pharmaceutical composition for manufacturing a medicine for treating a glycoprotein-related disease, wherein the pharmaceutical composition comprises: a first effective amount of phenol red and a second effective amount of an organic arsenic compound. 
         [0017]    Phenol red is known as an acid-base indicator and a diagnosis medicine. The arsenic compound is known as a medicine for treating syphilis, a blood agent, an herbicide and an insecticide. 
         [0018]    In the present disclosure, the phenol red and the organic arsenic compound are co-used to inhibit the interaction between carbohydrates and proteins and the glycosylation on proteins in pathogens. 
         [0019]    When the phenol red and the organic arsenic compound are co-used, the glycosylation pathway between the carbohydrates (such as sugar, starch and cellulose) and proteins, nucleoside and enzyme of pathogens (such as snake venom, prion, insect venom, reptile venom, virus and abnormal cells) can be inhibited; and the diseases and disorders caused by the pathogens can be inhibited. Hence, the combination of the phenol red and the organic arsenic compound can be used to treat or prevent virus infection (including DN and RNA viruses with different structures and shapes), snake venom infection (including hemorrhagic venom infection and neurotoxic venom infection), prion infection (including bovine spongiform encephalopathy, scrapie, and creutzfeldt-Jakob disease), insect venom infection (including mosquito&#39;s infection, bee&#39;s venom infection, scorpion&#39;s venom infection, spider&#39;s venom infection, centipede&#39;s venom infection, ant&#39;s venom infection, and staphylinidae&#39;s venom infection), reptile venom infection, a disease caused by abnormal eye cells (including cataract and retinopathy), a disease caused by abnormal brain cells (including Alzheimer&#39;s Disease and Parkinson&#39;s disease), and cell metabolism-related diseases (including pancreatitis, kidney inflammation, hepatitis, and cholangitis) occurred in vertebrate (preferably, mammalian). 
         [0020]    In the present disclosure, when the pharmaceutical composition of the phenol red and the organic arsenic compound are used, the treating efficacy of the combination is better than that of the organic arsenic compound alone, and the application field of the pharmaceutical composition is also larger than that of the organic arsenic compound alone. In addition, in the present disclosure, the experimental results indicate the pharmaceutical composition of the present disclosure has good treating effect on various diseases caused by different pathogens. The reason is that the active ingredients can combine with the receptors of the glycoproteins in the pathogens, enter into the proteomic of the pathogens, and then restrict the localizations of the protein particles. Next, the morphology of the protein particles is changed, and the activity thereof is loss. Hence, the pathogens cannot perform their metabolism and synthesis in the host cells, the polymerization of amino acids for forming proteins is inhibited, and then the glycosylation of the pathogens is further inhibited, resulting in the structure of the protein changed, the apoptosis of the proteins, and the synthesis, replication and differentiation of the pathogens inhibited. Therefore, the glycosylation pathway between the carbohydrates (such as sugar, starch and cellulose) and proteins, nucleoside and enzyme of the pathogens can be inhibited, and the diseases and disorders caused by the pathogens can be inhibited when the pharmaceutical composition of the present disclosure is used. 
         [0021]    In addition, the phenol red in the pharmaceutical composition of the present disclosure can be used as a stabilizer of the organic arsenic compound (such as monosodium methanearsonate). 
         [0022]    In the present disclosure, the phenol red and the organic arsenic compound can be combined into one formulation, or used in two separated formulations. 
         [0023]    In the present disclosure, the organic arsenic compound can be selected from the group consisting of monosodium methanearsonate, methylarsonic acid, sodium dimethylarsonate, disodium methylarsonate, cacodylic acid, and calcium acid methanearsonate. 
         [0024]    In the present disclosure, the phenol red has molecular weight of 354, and CAS No. thereof is 143-74-8. Monosodium methanearsonate has molecular weight of 162, and CAS No. thereof is 2163-80-6. 
         [0025]    In the present disclosure, the glycoprotein-related disease can be caused by various viruses. Herein, the viruses classified by National Center for Biotechnology Information, U.S. are listed below. 
       Family: Retroviridae 
       [0026]    Subfamily: Orthoretrovirinae
       Genus: Alpharetrovirus
           species: Avian leukosis virus   
           Genus: Betaretrovirus
           species: Jaagsiekte sheep retrovirus   
           Genus: Deltaretrovirus
           species: Bovine leukemia virus   species: Primate T-lymphotropic virus 1   species: Primate T-lymphotropic virus 2   species: Primate T-lymphotropic virus 3   
           Genus: Gammaretrovirus
           species: Feline leukemia virus   species: Gibbon ape leukemia virus (GALV)   species: Porcine type-C oncovirus   
           Genus: Lentivirus
           species: Bovine immunodeficiency virus   species: Equine infectious anemia virus   species: Feline immunodeficiency virus   species: Human immunodeficiency virus 1   species: Human immunodeficiency virus 2   species: Puma lentivirus   species: Simian immunodeficiency virus   species: Visna/maedi virus   
               
 
         [0049]    Subfamily: Spumaretrovirinae
       Genus: Spumavirus
           species: African green monkey simian foamy virus   species: Bovine foamy virus   species: Equine foamy virus   species: Feline foamy virus   species: Macaque simian foamy virus   species: Simian foamy virus   
               
 
       Family: Parvoviridae 
       [0057]    Subfamily: Parvovirinae
       Genus: Aveparvovirus
           species: Chicken parvovirus   species: Chicken parvovirus ABU-P1   species:  Gallus gallus  enteric parvovirus   species: Turkey parvovirus 260   
           Genus: Bocaparvovirus
           species: Pinniped bocaparvovirus 1   species: Pinniped bocaparvovirus 2   species: Primate bocaparvovirus 1   species: Primate bocaparvovirus 2   species: Ungulate bocaparvovirus 1   species: Ungulate bocaparvovirus 2   species: Ungulate bocaparvovirus 3   species: Ungulate bocaparvovirus 4   species: Ungulate bocaparvovirus 5   
           Genus: Copiparvovirus
           species: Ungulate copiparvovirus 1   species: Ungulate copiparvovirus 2   
           Genus: Erythroparvovirus
           species: Primate erythroparvovirus 1   species: Primate erythroparvovirus 2   species: Primate erythroparvovirus 3   species: Primate erythroparvovirus 4   species: Ungulate erythroparvovirus 1   
           Genus: Protoparvovirus
           species: Canine parvovirus   species: Feline panleukopenia virus (strain 193)   species: Porcine parvovirus   
           Genus: Tetraparvovirus
           species: Primate tetraparvovirus 1   species: Ungulate tetraparvovirus 1   species: Ungulate tetraparvovirus 2   species: Ungulate tetraparvovirus 3   species: Ungulate tetraparvovirus 4   
               
 
       Family: Paramyxoviridae 
       [0092]    Subfamily: Paramyxovirinae
       Genus: Avulavirus
           species: Avian paramyxovirus 2   species: Avian paramyxovirus 3   species: Avian paramyxovirus 4   species: Avian paramyxovirus 5   species: Avian paramyxovirus 6   species: Avian paramyxovirus 7   species: Avian paramyxovirus 8   species: Avian paramyxovirus 9   species: Avian paramyxovirus 10   species: Avian paramyxovirus 11   species: Avian paramyxovirus 12   species: Newcastle disease virus   
           Genus: Hen ipavirus
           species: Hendra virus   species: Nipah virus   
           Genus: Morbillivirus
           species: Canine distemper virus   species: Measles virus   species: Rinderpest virus   
           Genus: Respirovirus
           species: Bovine parainfluenza virus 3   species: Human parainfluenza virus 1   species: Human parainfluenza virus 3   species: Porcine parainfluenza virus 1   species: Sendai virus   
           Genus: Rubulavirus
           species: Human parainfluenza virus 2   species: Human parainfluenza virus 4   species: Mapuera virus   species: Mumps virus   species: Parainfluenza virus 5   species: Porcine rubulavirus   species: Simian virus 41   
               
 
         [0127]    Subfamily: Pneumovirinae
       Genus: Metapneumovirus
           species: Avian metapneumovirus   species: Human metapneumovirus   
           Genus: Orthopneumovirus
           species: Bovine respiratory syncytial virus   species: Human respiratory syncytial virus   species: Murine pneumonia virus   
           Genus: Pneumovirus
           species: Canine pneumovirus   species: Feline pneumovirus   species: Human respiratory syncytial virus A   species: Human respiratory syncytial virus B   species: Human respiratory syncytial virus S2   species: Human respiratory syncytial virus strain RSS-2   species: Human respiratory syncytial virus MinA   species: Human respiratory syncytial virus MinB   species: Human respiratory syncytial virus MinFLC   species: Human respiratory syncytial virus MinL   species: Ovine respiratory syncytial virus   species: Pneumovirus dog/Ane4/USA/2008   species: Pneumovirus dog/Bme17/USA/2008   species: Pneumovirus HFR-2013   species: Respiratory syncytial virus type A   
               
 
       Family: Coronaviridae 
       [0151]    Subfamily: Coronavirinae
       Genus: Alphacoronavirus
           species: Canine coronavirus   species: Feline coronavirus   species: Human coronavirus 229E   species: Human coronavirus NL63   species: Porcine epidemic diarrhea virus   species: Transmissible gastroenteritis virus   
           Genus: Betacoronavirus
           species: Bovine coronavirus   species: Canine respiratory coronavirus   species: Equine coronavirus   species: Human coronavirus OC43   species: Porcine hemagglutinating encephalomyelitis virus   species: Human coronavirus HKU1   species: Human coronavirus type 5   species: Middle East respiratory syndrome coronavirus   species: Severe acute respiratory syndrome-related coronavirus   
           Genus: Deltacoronavirus
           species: Porcine coronavirus HKU15   
           Genus: Gammacoronavirus
           species: Duck coronavirus   species: European turkey coronavirus 080385d   species: Goose coronavirus   species: Infectious bronchitis virus   species: Pheasant coronavirus   species: Pigeon coronavirus   species: Turkey coronavirus   
               
 
         [0179]    Subfamily: Torovirinae
       Genus: Torovirus
           species: Bovine torovirus   species: Equine torovirus   species: Human torovirus   species: Porcine torovirus   
               
 
       Family: Herpesviridae 
       [0185]    Subfamily: Alphaherpesvirinae
       Genus: Iltoviru
           species: Gallid herpesvirus 1   species: Psittacid herpesvirus 1   
           Genus: Mardivirus
           species: Anatid herpesvirus 1   species: Columbid herpesvirus 1   species: Gallid herpesvirus 2   species: Gallid herpesvirus 3   species: Meleagrid herpesvirus 1 (Turkey herpesvirus)   
           Genus: Simplexvirus
           species: Bovine herpesvirus 2   species: Human herpesvirus 1 (Herpes simplex virus type 1)   species: Human herpesvirus 2   species: Macacine herpesvirus 1 (monkey B virus)   
           Genus: Varicellovirus
           species: Bovine herpesvirus 1   species: Bovine herpesvirus 5   species: Canid herpesvirus 1   species: Caprine herpesvirus 1 (goat herpesvirus)   species: Equid herpesvirus 1 (Equine herpesvirus 1)   species: Equid herpesvirus 3   species: Equid herpesvirus 4 (Equine herpesvirus 4)   species: Equid herpesvirus 8   species: Equid herpesvirus 9   species: Felid herpesvirus 1   species: Human herpesvirus 3 (Varicella-zoster virus)   species: Suid herpesvirus 1 (Pseudorabies virus)   
               
 
         [0213]    Subfamily: Betaherpesvirinae
       Genus: Cytomegalovirus
           species: Aotine herpesvirus 1   species: Cebine herpesvirus 1   species: Human herpesvirus 5 (Human cytomegalovirus)   species: Macacine herpesvirus 3 (Rhesus cytomegalovirus)   species: Panine herpesvirus 2 (Chimpanzee cytomegalovirus)   
           Genus: Proboscivirus
           species: Elephantid herpesvirus 1   
           Genus: Roseolovirus
           species: Human herpesvirus 6A   species: Human herpesvirus 6B   species: Human herpesvirus 7   
               
 
         [0226]    Subfamily: Gammaherpesvirinae
       Genus: Lymphocryptovirus
           species: Human herpesvirus 4 (Epstein-Barr virus)   
           Genus: Macavirus
           species: Bovine herpesvirus 6   species: Caprine herpesvirus 2   species: Ovine herpesvirus 2   
           Genus: Percavirus
           species: Equid herpesvirus 2 (Equine herpesvirus 2)   species: Equid herpesvirus 5   
           Genus: Rhadinovirus
           species: Bovine herpesvirus 4   species: Human herpesvirus 8   
               
 
         [0239]    In the present disclosure, a pharmaceutical acceptable carrier can be further administered to the subject in need thereof. Hence, the pharmaceutical composition of the present disclosure may further comprises the pharmaceutical acceptable carrier. Herein, the pharmaceutical acceptable carrier is selected from the group consisting of solvent, buffer (such as phosphate buffered saline (PBS), Ringer&#39;s solution and Hank&#39;s solution), suspending agent, decomposer, disintegrating agent, dispersing agent, binding agent, excipient, stabilizing agent, chelating agent, diluent, gelling agent, preservative, lubricant, absorption delaying agent, and liposome. 
         [0240]    In the present disclosure, the pharmaceutical composition can be formulated into any formulation known in the art. The formulations comprise, but are not limited to: injection (for example, sterile aqueous solution or dispersion), sterile powder, tablet, troche, patch, lozenge, capsule, dispersible powder or granule, solution, suspension, emulsion, syrup, elixir, slurry and the like. 
         [0241]    In the present disclosure, the term “treating” or refers to administering the phenol red and the organic arsenic compound to a subject, who has an above-described disease, a symptom of such a disease, or a predisposition toward such a disease, with the purpose to confer a therapeutic effect, e.g., to cure, relieve, alter, affect, ameliorate, or prevent the above-described disease, the symptom of it, or the predisposition toward it. 
         [0242]    In the present disclosure, the term “a first or second effective amount” refers to the amount of the phenol red or the organic arsenic compound that is required to confer a therapeutic effect on the treated subject. Effective amounts may vary, as recognized by those skilled in the art, depending on the types of diseases treated, route of administration, excipient usage, and the possibility of co-usage with other agents. 
         [0243]    In the present disclosure, the phenol red and the organic arsenic compound can be administered via any known rout known in the art, for example, parenteral routes, intraperitoneal injection, subcutaneous injection, intramuscular injection and intravenous injection. Preferably, the phenol red and the organic arsenic compound are administered via intramuscular injection or intravenous injection. 
         [0244]    In the present disclosure, the dose and the administering times of the phenol red and the organic arsenic compound can be varied based on the following factors: the severity of the disease to be treated, the administering rout, and the age, condition and reaction of the subject to be treated. Generally, the dose of the phenol red and the organic arsenic compound is administered based on the bodyweight of the subject, and can be administered in a single dosage or several dosages, as long as the phenol red and the organic arsenic compound are administered at the same time or within several minutes. 
         [0245]    In the present disclosure, the first effective amount of the phenol red is not particularly limited, and can be adjusted according to the severity of the disease. Preferably, the first effective amount is ranged from 0.1 mg to 5.0 mg per kilograms of the subject in need thereof. More preferably, the first effective amount is ranged from 0.5 mg to 1.5 mg per kilograms of the subject in need thereof. 
         [0246]    In the present disclosure, the second effective amount of the organic arsenic compound is also not particularly limited, and can be adjusted according to the severity of the disease. Preferably, the second effective amount is ranged from 0.1 mg to 10.0 mg per kilograms of the subject in need thereof. More preferably, the second effective amount is ranged from 0.8 mg to 2.0 mg per kilograms of the subject in need thereof. 
         [0247]    In the present disclosure, when the phenol red is formulated into a solution, the first effective amount is ranged from 0.1 mg/cc to 5.0 mg/cc, and preferably from 0.8 mg/cc to 3.0 mg/cc. 
         [0248]    In addition, in the present disclosure, when the organic arsenic compound is formulated into a solution, the second effective amount is ranged from 0.1 mg/cc to 10.0 mg/cc, and preferably from 2.0 mg/cc to 6.0 mg/cc. 
         [0249]    Other objects, advantages, and novel features of the invention will become more apparent from the following detailed description when taken in conjunction with the accompanying drawings. 
     
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
         [0250]      FIG. 1  is a FIGURE showing the leukocyte amount changes of the FIV infected cat during the treatment according to Embodiment 1 of the present disclosure. 
       
    
    
     DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT 
       [0251]    The present invention has been described in an illustrative manner, and it is to be understood that the terminology used is intended to be in the nature of description rather than of limitation. Many modifications and variations of the present invention are possible in light of the above teachings. Therefore, it is to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described. 
         [0252]    In the following embodiments, a solution containing phenol red (2 mg/cc) and monosodium methanearsonate (4 mg/cc) is used, which is named as “LuMC5”, hereinafter. In addition, a solution containing monosodium methanearsonate (4 mg/cc) alone is also used, which is named as “MASA”, hereinafter. It should be noted that the following embodiments only provide one formulation of the pharmaceutical composition of the present disclosure. A person skilled in the art knows that the concentration of the active ingredients and the contents of the pharmaceutical composition can be adjusted within the scope of the appended claims. 
       Embodiment 1 
       [0253]    In the present embodiment, feline immunodeficiency virus (FIV) which is belonged to the same family (Retroviridae) and the same genus (Lentivirus) to HIV, was selected to perform the present clinical experiment. LuMC5 was administered to the infected cat via intravenous injection or intramuscular injection, 0.4 cc/kg, once or twice a day. The results are shown in the following Table 1 and  FIG. 1 . 
         [0000]    
       
         
               
             
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
               
             
           
               
                 TABLE 1 
               
               
                   
               
               
                 Blood cells examination data of FIV infected cat during 
               
               
                 the treatment (Testing company: LEZEN Reference Lab) 
               
               
                   
               
             
             
               
                   
               
             
          
           
               
                   
                 WBC 
                 NEU 
                 LYM 
                 MONO 
                 EOSI 
                 BASO 
               
               
                   
               
               
                 Day 1 
                 530 
                 18.9 
                 43.4 
                 37.7 
                 0 
                 0 
               
               
                 Day 3 
                 12790 
                 73 
                 10 
                 6.6 
                 0.3 
                 0.1 
               
               
                 Day 9 
                 31670 
                 80 
                 9 
                 6 
                 4.9 
                 0.1 
               
               
                 Day 34 
                 9000 
                 69 
                 24 
                 5 
                 2 
                 0.1 
               
               
                   
               
             
          
           
               
                   
                 RBC 
                 Hgb 
                 HCT 
                 M.C.V 
                 M.C.H 
                 M.C.H.C 
                 PLT 
               
               
                   
               
               
                 Day 1 
                 7.84 
                 12.1 
                 44.5 
                 56.8 
                 15.4 
                 27.2 
                 56 
               
               
                 Day 3 
                 7.7 
                 11.9 
                 42.1 
                 54.7 
                 15.5 
                 28.3 
                 165 
               
               
                 Day 9 
                 6.82 
                 10.6 
                 34.8 
                 51 
                 15.5 
                 30.5 
                 132 
               
               
                 Day 34 
                 6.71 
                 10.2 
                 37.5 
                 55.9 
                 15.2 
                 27.2 
                 38 
               
               
                   
               
               
                 NEU: Neutrophils/LYM: Lymphocytes/MONO: Monocytes/EOSI: Eosinophils/BASO: Basophils/Hg: Hemoglobin/HCT: Hematocrit/ 
               
             
          
         
       
     
         [0254]    From the results shown in  FIG. 1  and Table 1, the immune cell amount was increased rapidly at Day 3. In addition, acquired immune deficiency syndromes caused by FIV, such as toxoplasmosis,  pneumocystis  pneumonia and tumors were not found. The FIV infected cat turned into a healthy carrier after treatment. 
         [0255]    In addition, LuMC5 can be administered to the FIV infected cat for 4 to 14 days. No virus is detected after 4 to 14 days. Hence, LuMC5 can be administered when the virus levels in the FIV infected cat is high to control the syndromes, and is not have to be administered for a long term. Therefore, the immune system of the FIV infected cat is not destroyed. 
         [0256]    Therefore, when LuMC5 is used for treating the FIV infected subject, the development of the acquired immune deficiency syndromes caused by FIV can be inhibited; and the complication such as toxoplasmosis and  pneumocystis  pneumonia can be inhibited. Hence, the purposes of treatment and prevention can be accomplished. 
       Embodiment 2 
       [0257]    In the present embodiment, MASA and LuMC5 were used to treat the virus infected vertebrate and mammalian. 7 virus species belonged to 5 families were selected to perform the present clinical experiment. Herein, the virus classification is on the basis of National Center for Biotechnology Information, U. S. 
         [0000]    Subject: Infected dogs and cates sent to Hei-Ming Veterinary Hospital, Taiwan
 
7 virus species for clinical experiments:
 
       Family: Retroviridae 
       [0000]    
       
         
           
             Genus: Gammaretrovirus
           species: Feline leukemia virus   
         
             Genus: Lentivirus
           species: Feline immunodeficiency virus   
         
           
         
       
     
       Family: Parvoviridae 
       [0000]    
       
         
           
             species: Canine parvovirus 
             species: Feline panleukopenia virus 
           
         
       
     
       Family: Paramyxoviridae 
       [0000]    
       
         
           
             Genus: Morbillivirus
           species: Canine distemper virus   
         
           
         
       
     
       Family: Coronaviridae 
       [0000]    
       
         
           
             Genus: Alphacoronavirus
           species: Feline coronavirus   
         
           
         
       
     
       Family: Herpesviridae 
       [0000]    
       
         
           
             Genus: Varicellovirus
           species: Felid herpesvirus 1
 
Treatment: Intravenous injection or intramuscular injection, 0.4 cc/kg, once or twice a day
 
Testing company: Genomics BioSci &amp; TechCo., Ltd. (Abbreviation: G)
   
         
             MountainVet Biotech Co., Ltd. (Abbreviation: M) 
             VETE Co., Ltd. (Abbreviation: V) 
             LEZEN Reference Lab (Abbreviation: L)
 
Testing instrument: Real-time quantitative PCR detecting system (sensitivity &gt;99%) for G and M companies; and PCR or RT-PCR for V company
 
Testing method: The detected genes are the long terminal repeat (LTR) gene of Feline immunodeficiency virus, the virus protein 2 (VP2) gene of Canine parvovirus and the nucleocapsid gene (N gene) of Canine distemper virus. The virus amount is a curve calculated by the cycle threshold (C t ) values of the obtained PCR products based on the cycle threshold (C t ) values of the standard with predetermined different concentrations.
 
           
         
       
     
         [0273]    The testing results of the aforementioned 7 viruses in the clinical experiments are listed in the following Tables 2-1 to 2-7. 
         [0000]    
       
         
               
             
               
               
               
               
               
               
               
               
               
             
           
               
                 TABLE 2-1 
               
             
             
               
                   
               
               
                 Results of the clinical experiments on Feline leukemia virus 
               
             
          
           
               
                 Animal 
                   
                   
                   
                 Total 
                 Detecting 
                 Results 
                   
                   
               
               
                 &amp; ID 
                 Age 
                 Gender 
                 Medicine 
                 Days 
                 point 
                 (ng/uL) 
                 Specimen 
                 Company 
               
               
                   
               
               
                 Cat 
                 2 
                 M 
                 MSMA 
                 9 
                 Day 0 
                 + (* a)   
                 Blood 
                 V 
               
               
                 130730 
                 Years 
                   
                   
                   
                 Day 9 
                 − (* b)   
                   
                   
               
               
                 Cat 
                 7 
                 F 
                 LuMC5 
                 9 
                 Day 0 
                 222.8 × 10 −7   
                 Blood 
                 M 
               
               
                 160312 
                 Years 
                   
                   
                   
                  Day 11 
                 98.75 × 10 −7   
                   
                   
               
               
                 Cat 
                 1 
                 F 
                 LuMC5 
                 7 
                 Day 0 
                 248.8 × 10 −7   
                 Blood 
                 M 
               
               
                 150903 
                 Years 
                   
                   
                   
                 Day 9 
                 87.51 × 10 −7   
                   
                   
               
               
                 Cat 
                 2 
                 F 
                 LuMC5 
                 6 
                 Day 0 
                 261.4 × 10 −7   
                 Blood 
                 M 
               
               
                 160729 
                 Months 
                   
                   
                   
                 Day 4 
                  74.6 × 10 −7   
                   
                   
               
               
                   
                   
                   
                   
                   
                 Day 6 
                  53.6 × 10 −7   
               
               
                   
               
             
          
         
       
     
         [0000]    
       
         
               
             
               
               
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
               
               
             
           
               
                 TABLE 2-2 
               
             
             
               
                   
               
               
                 Results of the clinical experiments on feline immunodeficiency virus 
               
             
          
           
               
                 Animal 
                   
                   
                   
                 Total 
                 Detecting 
                 Results 
                   
                   
               
               
                 &amp; ID 
                 Age 
                 Gender 
                 Medicine 
                 Days 
                 point 
                 (ng/uL) 
                 Specimen 
                 Company 
               
               
                   
               
             
          
           
               
                 Cat 
                 2 
                 M 
                 MSMA 
                 9 
                 Day 0 
                 + (* a)   
                 Blood 
                 V 
               
               
                 130730 
                 Years 
                   
                   
                   
                 Day 9 
                 − (* b)   
                   
                   
               
               
                 Cat 
                 7 
                 F 
                 MSMA 
                 14 
                 Day 0 
                 + (* a)   
                 Blood 
                 V 
               
               
                 130805 
                 Months 
                   
                   
                   
                  Day 14 
                 − (* b)   
                   
                   
               
               
                 Cat 
                 7 
                 F 
                 LuMC5 
                 9 
                 Day 0 
                 45.75 × 10 −7   
                 Blood 
                 M 
               
               
                 160312 
                 Years 
                   
                   
                   
                  Day 11 
                 • 
                   
                   
               
               
                 Cat 
                 2 
                 F 
                 LuMC5 
                 6 
                 Day 0 
                  34.8 × 10 −7   
                 Blood 
                 M 
               
               
                 160729 
                 Months 
                   
                   
                   
                 Day 4 
                 • 
                   
                   
               
               
                   
                   
                   
                   
                   
                 Day 6 
                 • 
               
               
                   
               
             
          
         
       
     
         [0000]    
       
         
               
             
               
               
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
               
               
             
           
               
                 TABLE 2-3 
               
             
             
               
                   
               
               
                 Results of the clinical experiments on canine parvovirus 
               
             
          
           
               
                 Animal 
                   
                   
                   
                 Total 
                 Detecting 
                 Results 
                   
                   
               
               
                 &amp; ID 
                 Age 
                 Gender 
                 Medicine 
                 Days 
                 point 
                 (ng/uL) 
                 Specimen 
                 Company 
               
               
                   
               
             
          
           
               
                 Dog 
                 6 
                 F 
                 MSMA 
                 4 
                 Day 0 
                 932918 × 10 −8    
                 Feces (*c) 
                 G 
               
               
                 140529 
                 Months 
                   
                   
                   
                 Day 4 
                 28836 × 10 −8    
                   
                   
               
               
                 Dog 
                 3 
                 F 
                 MSMA 
                 10 
                 Day 0 
                 458306 × 10 −8    
                 Blood 
                 M 
               
               
                 150716 
                 Months 
                   
                   
                   
                  Day 10 
                 2470 × 10 −8   
                 Feces (*d) 
                   
               
               
                 Dog 
                 2 
                 F 
                 MSMA 
                 10 
                 Day 0 
                 40724.24 × 10 −7    
                 Blood 
                 M 
               
               
                 150708 
                 Months 
                   
                   
                   
                 Day 8 
                 2696.9 × 10 −7   
                   
                   
               
               
                   
                   
                   
                   
                   
                  Day 15 
                 185.6 × 10 −7   
                   
                   
               
               
                 Dog 
                 1 
                 M 
                 MSMA 
                 7 
                 Day 0 
                 46322 × 10 −8    
                 Blood 
                 G 
               
               
                 150125 
                 year 
                   
                   
                   
                 Day 3 
                  345 × 10 −8   
                   
                   
               
               
                   
                   
                   
                   
                   
                 Day 5 
                     75 × 10 −8   
                   
                   
               
               
                   
                   
                   
                   
                   
                 Day 6 
                     40 × 10 −8   
                   
                   
               
               
                   
                   
                   
                   
                   
                  Day 11 
                 • 
                   
                   
               
               
                 Dog 
                 5 
                 F 
                 MSMA 
                 10 
                 Day 0 
                 105804 × 10 −8    
                 Blood 
                 G 
               
               
                 140413 
                 Months 
                   
                   
                   
                 Day 3 
                 3560 × 10 −8   
                   
                   
               
               
                   
                   
                   
                   
                   
                 Day 9 
                 5314 × 10 −8   
                   
                   
               
               
                   
                   
                   
                   
                   
                  Day 11 
                 183.7 × 10 −8   
                   
                   
               
               
                 Dog 
                 2 
                 M 
                 LuMC5 
                 3 
                 Day 0 
                 36630.6 × 10 −7    
                 Blood 
                 M 
               
               
                 151123 
                 Months 
                   
                   
                   
                 Day 3 
                 1111.5 × 10 −7   
                   
                   
               
               
                 Dog 
                 3 
                 M 
                 LuMC5 
                 5 
                 Day 0 
                 102094.9 × 10 −7    
                 Blood 
                 M 
               
               
                 160301 
                 Months 
                   
                   
                   
                 Day 5 
                 66.9 × 10 −7   
                   
                   
               
               
                 Dog 
                 5 
                 M 
                 LuMC5 
                 4 
                 Day 0 
                 62749.9 × 10 −7    
                 Blood 
                 M 
               
               
                 160308 
                 Months 
                   
                   
                   
                 Day 4 
                 7.61 × 10 −7   
                   
                   
               
               
                 Dog 
                 3 
                 M 
                 LuMC5 
                 4 
                 Day 0 
                 6.66 × 10 −7   
                 Blood 
                 M 
               
               
                 160311 
                 Months 
                   
                   
                   
                 Day 4 
                 • 
                   
                   
               
               
                 Dog 
                 5 
                 M 
                 LuMC5 
                 3 
                 Day 0 
                 6474.4 × 10 −7   
                 Blood 
                 M 
               
               
                 160324 
                 Years 
                   
                   
                   
                 Day 3 
                 87.7 × 10 −7   
                   
                   
               
               
                 Dog 
                 8 
                 F 
                 LuMC5 
                 4 
                 Day 0 
                 107633.3 × 10 −7    
                 Blood 
                 M 
               
               
                 160326 
                 Months 
                   
                   
                   
                 Day 3 
                 77.4 × 10 −7   
               
               
                   
               
             
          
         
       
     
         [0000]    
       
         
               
             
               
               
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
               
               
             
           
               
                 TABLE 2-4 
               
             
             
               
                   
               
               
                 Results of the clinical experiments on feline panleukopenia virus 
               
             
          
           
               
                 Animal 
                   
                   
                   
                 Total 
                 Detecting 
                 Results 
                   
                   
               
               
                 &amp; ID 
                 Age 
                 Gender 
                 Medicine 
                 Days 
                 point 
                 (ng/uL) 
                 Specimen 
                 Company 
               
               
                   
               
             
          
           
               
                 Cat 
                 3 
                 F 
                 MSMA 
                 12 
                 Day 0 
                 4240717 × 10 −8    
                 Feces (*c_) 
                 G 
               
               
                 150323 
                 Months 
                   
                   
                   
                 Day 6 
                 22391915 × 10 −8      
                   
                   
               
               
                   
                   
                   
                   
                   
                  Day 15 
                     711 × 10 −8   
                   
                   
               
               
                   
                   
                   
                   
                   
                  Day 21 
                   14 × 10 −8   
                   
                   
               
               
                 Cat 
                 3 
                 M 
                 MSMA 
                 10 
                 Day 0 
                 130942 × 10 −8    
                 Blood 
                 G 
               
               
                 141128 
                 Months 
                   
                   
                   
                 Day 6 
                  1088 × 10 −8   
                   
                   
               
               
                   
                   
                   
                   
                   
                 Day 7 
                   25 × 10 −8   
                   
                   
               
               
                   
                   
                   
                   
                   
                 Day 8 
                   79 × 10 −8   
                   
                   
               
               
                 Cat 
                 3 
                 F 
                 MSMA 
                 8 
                 Day 0 
                 143.67 × 10 −7   
                 Blood 
                 G 
               
               
                 140512 
                 Years 
                   
                   
                   
                 Day 7 
                 • 
                   
                   
               
               
                 Cat 
                 3 
                 F 
                 MSMA 
                 12 
                 Day 0 
                 121.7 × 10 −7   
                 Blood 
                 G 
               
               
                 150529 
                 Years 
                   
                   
                   
                  Day 15 
                 • 
                   
                   
               
               
                 Cat 
                 7 
                 M 
                 LuMC5 
                 7 
                 Day 0 
                 11.21 × 10 −7   
                 Feces (*c) 
                 M 
               
               
                 150826 
                 Months 
                   
                   
                   
                 Day 5 
                  2.47 × 10 −7   
                   
                   
               
               
                 Cat 
                 8 
                 M 
                 LuMC5 
                 8 
                 Day 0 
                 40784.1 × 10 −7   
                 Blood 
                 M 
               
               
                 160104 
                 Months 
                   
                   
                   
                 Day 8 
                 10.28 × 10 −7   
                   
                   
               
               
                 Cat 
                 8 
                 F 
                 LuMC5 
                 7 
                 Day 0 
                 4219.6 × 10 −7   
                 Blood 
                 M 
               
               
                 160108 
                 Months 
                   
                   
                   
                 Day 7 
                 78.91 × 10 −7   
               
               
                   
               
             
          
         
       
     
         [0000]    
       
         
               
             
               
               
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
               
               
             
           
               
                 TABLE 2-5 
               
             
             
               
                   
               
               
                 Results of the clinical experiments on canine distemper virus 
               
             
          
           
               
                 Animal 
                   
                   
                   
                 Total 
                 Detecting 
                 Results 
                   
                   
               
               
                 &amp; ID 
                 Age 
                 Gender 
                 Medicine 
                 Days 
                 point 
                 (ng/uL) 
                 Specimen 
                 Company 
               
               
                   
               
             
          
           
               
                 Dog 
                 4 
                 F 
                 MSMA 
                 14 
                 Day 0 
                 1341 × 10 −8   
                 Nasal 
                 G 
               
               
                 140701 
                 Months 
                   
                   
                   
                 Day 4 
                 334 × 10 −8   
                 secretion (*c) 
                   
               
               
                   
                   
                   
                   
                   
                  Day 10 
                 116 × 10 −8   
                   
                   
               
               
                   
                   
                   
                   
                   
                  Day 14 
                 • 
                   
                   
               
               
                 Dog 
                 4 
                 F 
                 MSMA 
                 12 
                 Day 0 
                  24 × 10 −8   
                 Nasal 
                 G 
               
               
                 140703 
                 Months 
                   
                   
                   
                 Day 3 
                 312 × 10 −8   
                 secretion (*c) 
                   
               
               
                   
                   
                   
                   
                   
                  Day 10 
                  61 × 10 −8   
                   
                   
               
               
                   
                   
                   
                   
                   
                  Day 12 
                 • 
                   
                   
               
               
                 Dog 
                 1 
                 F 
                 MSMA 
                 11 
                 Day 0 
                 310 × 10 −8   
                 Blood 
                 G 
               
               
                 140808 
                 Year 
                   
                   
                   
                 Day 7 
                 350 × 10 −8   
                   
                   
               
               
                   
                   
                   
                   
                   
                  Day 11 
                 • 
                   
                   
               
               
                 Dog 
                 7 
                 F 
                 MSMA 
                 12 
                 Day 0 
                 350 × 10 −8   
                 Blood 
                 G 
               
               
                 140808-1 
                 Years 
                   
                   
                   
                 Day 8 
                 264 × 10 −8   
                   
                   
               
               
                   
                   
                   
                   
                   
                  Day 12 
                 • 
                   
                   
               
               
                 Dog 
                 12 
                 M 
                 MSMA 
                 3 
                 Day 0 
                  28 × 10 −8   
                 Blood 
                 G 
               
               
                 140617 
                 Years 
                   
                   
                   
                 Day 3 
                 • 
               
               
                   
               
             
          
         
       
     
         [0000]    
       
         
               
             
               
               
               
               
               
               
               
               
               
             
           
               
                 TABLE 2-6 
               
             
             
               
                   
               
               
                 Results of the clinical experiments on feline coronavirus 
               
             
          
           
               
                 Animal 
                   
                   
                   
                 Total 
                 Detecting 
                 Results 
                   
                   
               
               
                 &amp; ID 
                 Age 
                 Gender 
                 Medicine 
                 Days 
                 point 
                 (ng/uL) 
                 Specimen 
                 Company 
               
               
                   
               
               
                 Cat 
                 5 
                 F 
                 MSMA 
                 8 
                 Day 0 
                 41733.8 × 10 −7   
                 Blood 
                 G 
               
               
                 150430 
                 Years 
                   
                   
                   
                 Day 8 
                 • 
                   
                   
               
               
                 Cat 
                 4 
                 M 
                 LuMC5 
                 8 
                 Day 0 
                 5691.51 × 10 −7   
                 Feces (*c) 
                 M 
               
               
                 150826 
                 Months 
                   
                   
                   
                 Day 5 
                  176.05 × 10 −7   
                   
                   
               
               
                   
                   
                   
                   
                   
                 Day 8 
                 • 
                   
                   
               
               
                 Cat 
                 5 
                 M 
                 LuMC5 
                 5 
                 Day 0 
                 10589.77 × 10 −7   
                 Blood 
                 M 
               
               
                 150903 
                 Months 
                   
                   
                   
                 Day 5 
                 • 
                   
                   
               
               
                 Cat 
                 7 
                 F 
                 LuMC5 
                 8 
                 Day 0 
                  125.8 × 10 −7   
                 Blood 
                 M 
               
               
                 160110 
                 Months 
                   
                   
                   
                 Day 8 
                 • 
                 Ascites 
               
               
                   
               
             
          
         
       
     
         [0000]                                                                                                TABLE 2-7                   Results of the clinical experiments on felid herpesvirus 1            Animal               Total   Detecting   Results               &amp; ID   Age   Gender   Medicine   Days   point   (ng/uL)   Specimen   Company                    Cat   1   M   MSMA   12   Day 0   1528214 × 10 −8      Blood   G       150417   Year               Day 4       214 × 10 −8                                      Day 13   •               Cat   5   M   MSMA   10   Day 0   151.8 × 10 −7     Nasal   G       150502   Months                Day 10    3.75 × 10 −7     secretion (*c)           Cat   3   F   MSMA   9   Day 0   27380 × 10 −7     Blood   G       150507   years               Day 7   •               Cat   8   F   MSMA   8   Day 0   2282.5 × 10 −7     Blood   G       150516   Months                Day 15   69.71 × 10 −7                 Cat   8   F   LuMC5   5   Day 0   326.1 × 10 −7     Blood   M       151224   Months               Day 5   •               Cat   11   F   LuMC5   6   Day 0   8911.7 × 10 −7     Blood   M       160315   Months               Day 6   661.6 × 10 −7                      
*a: “+” refers to viruses were found in the detection.
 
*b: “−” refers to viruses were not found in the detection.
 
*c: Not quantitative detection
 
: No pathogen infection or small amount of pathogens detected
 
         [0274]    The administered period of MASA was 4 days to 14 days (average 9 days). The administered period of LuMC5 was 3 days to 9 days (average 5.7 days). When LuMC5 was administered via subcutaneous injection, intramuscular injection or intravenous injection, the fever in the subject was reduced within 3 hours to 5 hours, and metal condition of the subject was improved. The virus level in the specimens thereof was greatly reduced to slight amount within 2 days to 5 days, and reduced from the slight amount to the amount incapable to be detected within 5 days to 8 days. The infection syndromes were rapidly improved. 
       Embodiment 3 
       [0275]    In the present embodiment, LuMC5 was used to treat the mammalian with hemorrhagic venom infection and neurotoxic venom. 
         [0000]    Subject: Infected dogs and cates sent to Hei-Ming Veterinary Hospital, Taiwan
 
Treatment: Intravenous injection or intramuscular injection, 0.4 cc/kg, once or twice a day
 
         [0276]    The testing results s in the clinical experiments of the present embodiment are listed in the following Tables 3-1 to 3-3. 
         [0000]    
       
         
               
             
               
               
               
               
               
               
             
           
               
                 TABLE 3-1 
               
             
             
               
                   
               
               
                 Results of the clinical experiments on the subject infected with 
               
               
                 hemorrhagic venom infection of  Trimeresurus mucrosquamatus   
               
             
          
           
               
                 Animal 
                   
                   
                 Time to 
                 Administered 
                 Syndromes before treatment 
               
               
                 &amp; ID 
                 Age 
                 Gender 
                 be treated 
                 times 
                 Condition after treatment 
               
               
                   
               
               
                 Dog 
                 3 
                 M 
                 2 hours 
                 1 
                 Depression, lifeless, sticky saliva, and 
               
               
                 130420 
                 years 
                   
                 after 
                   
                 facial and head swelling 
               
               
                   
                   
                   
                 infection 
                   
                 Depression and lifeless were relieved, 1 
               
               
                   
                   
                   
                   
                   
                 hours after treatment. 
               
               
                   
                   
                   
                   
                   
                 Facial and head swelling were relieved, 12 
               
               
                   
                   
                   
                   
                   
                 hours after treatment. 
               
               
                 Dog 
                 6 
                 F 
                 2 hours 
                 2 
                 Facial swelling, depression, lifeless, and 
               
               
                 140405 
                 years 
                   
                 after 
                   
                 mouth and tongue blood stasis 
               
               
                   
                   
                   
                 infection 
                   
                 Depression and lifeless were relieved, 30 
               
               
                   
                   
                   
                   
                   
                 minutes after treatment. 
               
               
                   
                   
                   
                   
                   
                 Facial swelling and mouth and tongue 
               
               
                   
                   
                   
                   
                   
                 blood stasis were relieved, 24 hours after 
               
               
                   
                   
                   
                   
                   
                 treatment. 
               
               
                 Cat 
                 1 
                 F 
                 1 hours 
                 2 
                 Shock, unconsciousness, tachypnoea, 
               
               
                 140320 
                 year 
                   
                 after 
                   
                 transparent and jelly-like saliva, and 
               
               
                   
                   
                   
                 infection 
                   
                 hematuria 
               
               
                   
                   
                   
                   
                   
                 Shock, unconsciousness, tachypnoea, and 
               
               
                   
                   
                   
                   
                   
                 transparent and jelly-like saliva were 
               
               
                   
                   
                   
                   
                   
                 relieved, 30 minutes after treatment. 
               
               
                   
                   
                   
                   
                   
                 Hematuria was relieved and the subject 
               
               
                   
                   
                   
                   
                   
                 became healthy, 50 minutes after 
               
               
                   
                   
                   
                   
                   
                 treatment. 
               
               
                 Dog 
                 3 
                 M 
                 26 hours 
                 2 
                 Depression, lifeless, sticky saliva, and chin 
               
               
                 140724 
                 years 
                   
                 after 
                   
                 swelling 
               
               
                   
                   
                   
                 infection 
                   
                 Depression, lifeless, and sticky saliva were 
               
               
                   
                   
                   
                   
                   
                 relieved, 50 minutes after treatment. 
               
               
                   
                   
                   
                   
                   
                 Chin swelling was relieved, 12 hours after 
               
               
                   
                   
                   
                   
                   
                 treatment. 
               
               
                 Dog 
                 4 
                 M 
                 4 hours 
                 1 
                 Bleed and depression 
               
               
                 140707 
                 years 
                   
                 after 
                   
                 Bleed caused by snakebite was relieved, 10 
               
               
                   
                   
                   
                 infection 
                   
                 minutes after treatment. 
               
               
                   
                   
                   
                   
                   
                 Depression was relieved, 30 minutes after 
               
               
                   
                   
                   
                   
                   
                 treatment. 
               
               
                 Dog 
                 4 
                 M 
                 4 hours 
                 1 
                 Bleed and depression 
               
               
                 140707-1 
                 years 
                   
                 after 
                   
                 Bleed caused by snakebite was relieved, 10 
               
               
                   
                   
                   
                 infection 
                   
                 minutes after treatment. 
               
               
                   
                   
                   
                   
                   
                 Depression was relieved, 30 minutes after 
               
               
                   
                   
                   
                   
                   
                 treatment. 
               
               
                 Dog 
                 7 
                 M 
                 16 hours 
                 2 
                 Depression, lifeless, sticky saliva, and 
               
               
                 141028 
                 years 
                   
                 after 
                   
                 facial and chin swelling 
               
               
                   
                   
                   
                 infection 
                   
                 Depression and lifeless were relieved, 30 
               
               
                   
                   
                   
                   
                   
                 minutes after treatment. 
               
               
                   
                   
                   
                   
                   
                 Facial and chin swelling was relieved, 12 
               
               
                   
                   
                   
                   
                   
                 hours after treatment. 
               
               
                   
               
             
          
         
       
     
         [0000]    
       
         
               
             
               
               
               
               
               
               
             
           
               
                 TABLE 3-2 
               
             
             
               
                   
               
               
                 Results of the clinical experiments on the subject infected with 
               
               
                 hemorrhagic venom infection of  Viridovipera stejnegeri   
               
             
          
           
               
                   
                   
                   
                   
                   
                 Syndromes 
               
               
                   
                   
                   
                   
                 Admin- 
                 before treatment 
               
               
                 Animal 
                   
                   
                 Time to 
                 istered 
                 Condition 
               
               
                 &amp; ID 
                 Age 
                 Gender 
                 be treated 
                 times 
                 after treatment 
               
               
                   
               
               
                 Dog 
                 1 
                 M 
                 14 hours 
                 3 
                 Depression, lifeless, 
               
               
                 140412 
                 year 
                   
                 after 
                   
                 sticky saliva, and 
               
               
                   
                   
                   
                 infection 
                   
                 facial and chin swelling 
               
               
                   
                   
                   
                   
                   
                 Depression and 
               
               
                   
                   
                   
                   
                   
                 lifeless were 
               
               
                   
                   
                   
                   
                   
                 relieved, 2 hours 
               
               
                   
                   
                   
                   
                   
                 after treatment. 
               
               
                   
                   
                   
                   
                   
                 Facial and chin 
               
               
                   
                   
                   
                   
                   
                 swelling was relieved, 
               
               
                   
                   
                   
                   
                   
                 24 hours after treatment. 
               
               
                   
               
             
          
         
       
     
         [0000]    
       
         
               
             
               
               
               
               
               
               
             
           
               
                 TABLE 3-3 
               
             
             
               
                   
               
               
                 Results of the clinical experiments on the subject infected with 
               
               
                 neurotoxic venom infection of  Naja   
               
             
          
           
               
                   
                   
                   
                   
                   
                 Syndromes 
               
               
                   
                   
                   
                   
                 Admin- 
                 before treatment 
               
               
                 Animal 
                   
                   
                 Time to 
                 istered 
                 Condition 
               
               
                 &amp; ID 
                 Age 
                 Gender 
                 be treated 
                 times 
                 after treatment 
               
               
                   
               
               
                 Dog 
                 6 
                 M 
                 2 hours 
                 2 
                 Depression, lifeless, 
               
               
                 140426 
                 years 
                   
                 after 
                   
                 sticky saliva, and 
               
               
                   
                   
                   
                 infection 
                   
                 facial and chin 
               
               
                   
                   
                   
                   
                   
                 swelling 
               
               
                   
                   
                   
                   
                   
                 Depression and lifeless 
               
               
                   
                   
                   
                   
                   
                 were relieved, 
               
               
                   
                   
                   
                   
                   
                 30 minutes after 
               
               
                   
                   
                   
                   
                   
                 treatment. 
               
               
                   
                   
                   
                   
                   
                 Facial and chin swelling 
               
               
                   
                   
                   
                   
                   
                 was relieved, 12 hours 
               
               
                   
                   
                   
                   
                   
                 after treatment. 
               
               
                   
               
             
          
         
       
     
         [0277]    From the results shown in the present embodiment, when LuMC5 was administered into the infected subject via subcutaneous injection, intramuscular injection or intravenous injection, the nose bleeding and sticky saliva can be relieved within 10 minutes, the depression can be relieved within 30 minutes, the hematuria can be relieved within 50 minutes, and the swelling can be relieved and the treated subject become healthy within 1 hours to 36 hours. Hence, by using LuMC5 of the present disclosure, the infection syndromes can be controlled. Compared to the conventional method by naturalizing toxins with serum formulation, in which antibodies are formed to identify and neutralize toxin proteins after 7 days to 14 days and the swelling syndrome is relieved after 7 days, LuMC5 of the present disclosure can relieve the syndromes in a short time and has superior treatment efficacy. 
       Embodiment 4 
       [0278]    In the present embodiment, LuMC5 was used to treat the mammalian that the mosquito, bee, scorpion, spider, centipede, ant, and staphylinidae bitten. 
         [0000]    Subject: Dog bit by bees, sent to Hei-Ming Veterinary Hospital, Taiwan, and having bodyweight of 27 Kg
 
Treatment: Intravenous injection or intramuscular injection, 0.4 cc/kg, twice a day
 
The result is shown in the following Table 4-1.
 
         [0000]    
       
         
               
               
               
               
               
               
             
           
               
                 TABLE 4-1 
               
               
                   
               
               
                   
                   
                   
                   
                   
                 Syndromes 
               
               
                   
                   
                   
                   
                 Admin- 
                 before treatment 
               
               
                 Animal 
                   
                   
                 Time to 
                 istered 
                 Condition 
               
               
                 &amp; ID 
                 Age 
                 Gender 
                 be treated 
                 times 
                 after treatment 
               
               
                   
               
             
             
               
                 Dog 
                 14 
                 F 
                 2 hours 
                 2 
                 Depression, lifeless, 
               
               
                 140414 
                 years 
                   
                 after 
                   
                 and facial and head 
               
               
                   
                   
                   
                 infection 
                   
                 swelling 
               
               
                   
                   
                   
                   
                   
                 Depression and lifeless 
               
               
                   
                   
                   
                   
                   
                 were relieved, 30 
               
               
                   
                   
                   
                   
                   
                 minutes after treatment 
               
               
                   
                   
                   
                   
                   
                 Facial and head swelling 
               
               
                   
                   
                   
                   
                   
                 was relieved, 12 hours 
               
               
                   
                   
                   
                   
                   
                 after treatment. 
               
               
                   
               
             
          
         
       
     
         [0279]    The treatment results show that the mental condition of the treated subject was improved, the appetite thereof was recovered, and the activity thereof such as tail shaking turned into normal, after treatment. 
         [0000]    Subject: Human bit by a mosquito, bodyweight: 79 Kg
 
Treatment: Applying LuMC5 at the mosquito biting region, twice a day
 
The result is shown in the following Table 4-2.
 
         [0000]    
       
         
               
               
               
               
               
               
             
           
               
                 TABLE 4-2 
               
               
                   
               
               
                   
                   
                   
                   
                   
                 Syndromes 
               
               
                   
                   
                   
                   
                 Admin- 
                 before treatment 
               
               
                 Animal 
                   
                   
                 Time to 
                 istered 
                 Condition 
               
               
                 &amp; ID 
                 Age 
                 Gender 
                 be treated 
                 times 
                 after treatment 
               
               
                   
               
             
             
               
                 Dog 
                 55 
                 F 
                 3 minutes 
                 2 
                 Swelling and itch at the 
               
               
                 160415 
                 years 
                   
                 after 
                   
                 biting region on the skin 
               
               
                   
                   
                   
                 infection 
                   
                 Itch was relieved, 3-20 
               
               
                   
                   
                   
                   
                   
                 minutes after applying 
               
               
                   
                   
                   
                   
                   
                 medicine. 
               
               
                   
                   
                   
                   
                   
                 Swelling was relieved, 
               
               
                   
                   
                   
                   
                   
                 1-3 hours after 
               
               
                   
                   
                   
                   
                   
                 applying medicine. 
               
               
                   
               
             
          
         
       
     
         [0280]    From the results shown in the present embodiment, LuMC5 can effectively relieve the itch and selling on the skin caused by the insects. If the subject is bit by the insects, the glycosylation of the virus can be inhibited when LuMC5 is applied immediately. In addition, the syndromes of venom allergy, fever and lifeless can be relieved by administering LuMC5 via injection. The swelling at the skin region bit by the insects with pathogens can be relieved by applying ointment or solution at the affected region. Therefore, Dengue virus, West Nile virus and Zika virus infection to human and animals can be effectively relieved and prevented by using LuMC5 of the present disclosure. 
       Embodiment 5 
       [0281]    In the present embodiment, LuMC5 was used to treat cataract and retinopathy caused by abnormal eye cells in mammalian. 
         [0000]    Subject: Infected dogs and cates sent to Hei-Ming Veterinary Hospital, Taiwan
 
Treatment: Solution containing 1-2 mg/cc of phenol red and 3-4 mg/cc of monosodium methanearsonate, one drop per time, twice or three times a day
 
The result is shown in the following Tables 5-1 and 5-2.
 
         [0000]    
       
         
               
             
               
               
               
               
               
               
             
           
               
                 TABLE 5-1 
               
             
             
               
                   
               
               
                 Results of the clinical experiments on Pomeranian with cataract 
               
             
          
           
               
                   
                   
                   
                   
                   
                 Syndromes 
               
               
                   
                   
                   
                   
                   
                 before treatment 
               
               
                 Animal 
                   
                   
                 Total 
                   
                 Condition 
               
               
                 &amp; ID 
                 Age 
                 Gender 
                 days 
                 Treatment 
                 after treatment 
               
               
                   
               
               
                 Dog 
                 18 
                 F 
                 46 
                 One drop 
                 Mature cataract, spin 
               
               
                 151013 
                 years 
                   
                   
                 per time, 
                 around while walking, 
               
               
                   
                   
                   
                   
                 three times a 
                 incapable of walking 
               
               
                   
                   
                   
                   
                 day 
                 straight, hitting the wall, 
               
               
                   
                   
                   
                   
                   
                 and recognizing 
               
               
                   
                   
                   
                   
                   
                 surrounding by smelling, 
               
               
                   
                   
                   
                   
                   
                 auditory sense and living 
               
               
                   
                   
                   
                   
                   
                 experience 
               
               
                   
                   
                   
                   
                   
                 The clouding of the lens 
               
               
                   
                   
                   
                   
                   
                 in the eye reduced. 
               
               
                   
                   
                   
                   
                   
                 The treated subject can 
               
               
                   
                   
                   
                   
                   
                 walk straight without 
               
               
                   
                   
                   
                   
                   
                 hitting the wall. 
               
               
                   
               
             
          
         
       
     
         [0000]    
       
         
               
             
               
               
               
               
               
               
             
           
               
                 TABLE 5-2 
               
             
             
               
                   
               
               
                 Results of the clinical experiments on Golden Retriever with 
               
               
                 cataract 
               
             
          
           
               
                   
                   
                   
                   
                   
                 Syndromes  
               
               
                   
                   
                   
                   
                   
                 before treatment 
               
               
                 Animal 
                   
                   
                 Total 
                   
                 Condition 
               
               
                 &amp; ID 
                 Age 
                 Gender 
                 days 
                 Treatment 
                 after treatment 
               
               
                   
               
               
                 Dog 
                 10 
                 M 
                 29 
                 One drop 
                 The subject cannot see 
               
               
                 160128 
                 years 
                   
                   
                 per time, 
                 the object at the long 
               
               
                   
                   
                   
                   
                 twice a day 
                 distance during daytime. 
               
               
                   
                   
                   
                   
                   
                 Visually impaired 
               
               
                   
                   
                   
                   
                   
                 during the night. 
               
               
                   
                   
                   
                   
                   
                 The clouding of the lens 
               
               
                   
                   
                   
                   
                   
                 in the eye reduced. 
               
               
                   
                   
                   
                   
                   
                 The subject&#39;s day and 
               
               
                   
                   
                   
                   
                   
                 night vision was 
               
               
                   
                   
                   
                   
                   
                 recovered. 
               
               
                   
               
             
          
         
       
     
       Embodiment 6 
       [0282]    In the present embodiment, LuMC5 was used to treat metabolism-related diseases (including pancreatitis, kidney inflammation, hepatitis, and cholangitis) occurred in mammalian. 
         [0000]    Subject: Infected dogs and cates sent to Hei-Ming Veterinary Hospital, Taiwan
 
Treatment: Intravenous injection or intramuscular injection, 0.4 cc/kg, once a day
 
Testing company: LEZEN Reference Lab
 
The result is shown in the following Tables 6-1 to 6-4.
 
         [0000]    
       
         
               
               
               
               
               
               
             
           
               
                 TABLE 6-1 
               
               
                   
               
               
                   
                   
                   
                   
                   
                 Syndromes 
               
               
                   
                   
                   
                   
                   
                 before treatment 
               
               
                 Animal 
                   
                   
                 Total 
                   
                 Condition 
               
               
                 &amp; ID 
                 Age 
                 Gender 
                 days 
                 Body weight 
                 after treatment 
               
               
                   
               
             
             
               
                 Dog 
                 15 
                 M 
                 11 
                 20 Kg 
                 Anorexia for 4-5 
               
               
                 160714 
                 years 
                   
                   
                   
                 days, urine in dark 
               
               
                   
                   
                   
                   
                   
                 brown, weakness, and 
               
               
                   
                   
                   
                   
                   
                 dehydration 
               
               
                   
                   
                   
                   
                   
                 Appetite and activity 
               
               
                   
                   
                   
                   
                   
                 recovered 
               
               
                   
               
             
          
         
       
     
         [0000]    
       
         
               
             
               
               
               
               
               
               
             
               
               
               
               
               
               
             
           
               
                 TABLE 6-2 
               
             
             
               
                   
               
               
                 Blood test data of Dog 160714 during the treatment 
               
             
          
           
               
                   
                   
                 Alkaline- 
                   
                   
                   
               
               
                   
                 PT:ALT 
                 p 
                 BUN 
                 Creatinine 
                 Amylase 
               
               
                   
                 (liver) 
                 (gall) 
                 (uremia) 
                 (Kidney) 
                 (pancreas) 
               
               
                   
                   
               
             
          
           
               
                 Day 1 
                 87 
                 87 
                 94.2 
                 3.44 
                 1447 
               
               
                 Day 19 
                 24 
                 50 
                 60 
                 2.78 
                 1225 
               
               
                 Reference 
                 14-40 U/L 
                 32-91 U/L 
                 8-20 
                 0.64-1.27 
                 S: 28-1200 
               
               
                   
                   
                   
                 mg/dL 
                 mg/dL 
                 U/L 
               
               
                   
               
             
          
         
       
     
         [0000]    
       
         
               
               
               
               
               
               
             
           
               
                 TABLE 6-3 
               
               
                   
               
               
                   
                   
                   
                   
                   
                 Syndromes 
               
               
                   
                   
                   
                   
                   
                 before treatment 
               
               
                 Animal 
                   
                   
                 Total 
                   
                 Condition 
               
               
                 &amp; ID 
                 Age 
                 Gender 
                 days 
                 Body weight 
                 after treatment 
               
               
                   
               
             
             
               
                 Dog 
                 15 
                 F 
                 3 
                 28 Kg 
                 Anorexia for 1-2 days, 
               
               
                 160805 
                 years 
                   
                   
                   
                 vomit, weakness, 
               
               
                   
                   
                   
                   
                   
                 incapable of standing 
               
               
                   
                   
                   
                   
                   
                 Capable of standing at 
               
               
                   
                   
                   
                   
                   
                 Day 2, eating small 
               
               
                   
                   
                   
                   
                   
                 amount of food, and 
               
               
                   
                   
                   
                   
                   
                 walking slowly at Day 3 
               
               
                   
               
             
          
         
       
     
         [0000]    
       
         
               
             
               
               
               
               
             
               
               
               
               
             
           
               
                 TABLE 6-4 
               
             
             
               
                   
               
               
                 Blood test data of Dog 160805 during the treatment 
               
             
          
           
               
                   
                   
                 Creatinine 
                 Amylase 
               
               
                 Item 
                 BUN (uremia) 
                 (Kidney) 
                 (pancreas) 
               
               
                   
               
             
          
           
               
                 2016 Aug. 5 
                 31.5 
                 2.46 
                 1251 
               
               
                 2016 Aug. 8 
                 21.5 
                 1.19 
                 931 
               
               
                 Reference 
                 8-20 mg/dL 
                 0.64-1.27 mg/dL 
                 S: 28-1200 U/L 
               
               
                   
               
             
          
         
       
     
         [0283]    From the results shown in Embodiments 5 and 6, a solution made from LuMC5 can be used to treat diseases caused by abnormal eye cells (such as cataract and retinopathy) by administering the solution at the predetermined time with a predetermined amount. When treating diseases caused by abnormal brain cells (including Alzheimer&#39;s Disease and Parkinson&#39;s disease), LuMC5 can be formulated into a paste or ointment and administered at the predetermined time with a predetermined amount. The skin absorbs the active ingredients, and the active ingredients can enter into the brain via the blood in the carotid artery to accomplish the purpose of preventing disease. When treating metabolism related diseases (such as pancreatitis, kidney inflammation, hepatitis, as cholangitis), LuMC5 can be administered via subcutaneous injection, intramuscular injection or intravenous injection for 5 to 7 days, and the swelling and inflammation can be effectively relieved. 
       Embodiment 7 
       [0284]    When treating prion infection (including bovine spongiform encephalopathy, scrapie, and creutzfeldt-Jakob disease), LuMC5 can be formulated into a paste or ointment and administered at the predetermined time with a predetermined amount. The skin absorbs the active ingredients, and the active ingredients can enter into the brain via the blood in the carotid artery to accomplish the purpose of preventing disease. 
         [0285]    Although the present invention has been explained in relation to its preferred embodiment, it is to be understood that many other possible modifications and variations can be made without departing from the spirit and scope of the invention as hereinafter claimed.